Business
Clene to Provide CNM-Au8® ALS Program Update
Webcast set for 8:30 a.m. ET on December 3rdSALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced it plans provide an update on its CNM-Au8 program in ALS, and to host an
About this update from Clene Inc.
[{"type":"image","alt":"Clene Inc.","displaySize":"","headline":null,"caption":"Clene Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":72,"url":"https://media.zenfs.com/en/globenewswire.com/6ecbc5bc1ea840a1a7b45cd42deb4188"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dqllcqG43QFquU0vfLNVhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6ecbc5bc1ea840a1a7b45cd42deb4188","width":300,"height":72}},"lazy":false},{"type":"text","content":"Webcast set for 8:30 a.m. ET on December 3rd","length":44,"tagName":"p"},{"type":"text","content":"SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced it plans provide an update on its CNM-Au8 program in ALS, and to host an investor call and webcast at 8:30 am ET on Wednesday, December 3, 2025. The webcast is accessible via the link below or the Investors section of the Company’s website located here.","length":641,"tagName":"p"},{"type":"text","content":"Webcast Information:Title: CNM-Au8 ALS Program Update Presenters: Rob Etherington, CEO and President, Dr. Ben Greenberg, Head of Medical, Michael Hotchkin, Chief Development Officer and a KOLDate: December 3, 2025Start Time: 8:30 a.m. ETWebcast link: https://viavid.webcasts.com/starthere.jsp?ei=1744985&tp_key=9fb9583d33Dial number: 1-877-407-0779 (US) or 1-201-389-0914 (international), Conference ID#13757380","length":421,"tagName":"p"},{"type":"text","content":"The archived webcast will be available on the Company's website beginning approximately two hours after the event.","length":118,"tagName":"p"},{"type":"text","content":"About CleneClene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc.), is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational...